Argos Therapeutics Inc (NASDAQ: ARGS)

Lloyd Doyle
October 21, 2017

The stock exchanged hands 2.31 Million shares versus average trading capacity of 2.19 Million shares.

While under theory that management are shareholders, many value investors look for stocks with a high percent of insider ownership, because they will act in its own self interest, as well create shareholder value in the long-term. Earnings surprises can have a huge impact on a company's stock price.

Coeur Mining Inc (NYSE:CDE) has average revenue estimates of $185.09 Million, compared to low analyst estimates of $173 Million and high estimates of $200 Million for the current quarter. The number of shares now owned by investors are 51.37 mln. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.10 million.

The current price is staying above the SMA lines which signify strength and is generally healthy/positive and may provide the momentum for driving the share price higher. The stock now has a consensus rating of "Hold" and an average target price of $4.13. (BZUN) is performing 179.12%. The Weekly and Monthly Volatility stands at 6.41% and 8.84%.

Argos Therapeutics, Inc. (NASDAQ:ARGS) has a 20-day RSI of 39.68%. It's now trading about -97.01% below its 52-week high. ARGS's average trading volume during the past 20 days is lower than the average volume over the past 100 days, which could be an indication that investors are feeling less certain than usual about the direction of ARGS's future price movements. Sell-side analyst recommendations point to a short term price target of $ on the company shares. Three months ago, analysts assigned ARGS a 3.00 rating, which implies that analysts largely still feel the same about the outlook for the stock over the next year. Its minimum price target estimates has been figured out at $8.5 while the maximum price target forecast is established at $14.

Insider Trades for Argos Therapeutics, Inc. show that the latest trade was made on 29 Aug 2017 where Katz (Richard D), the Chief Financial Officer completed a transaction type "Buy" in which 395664 shares were traded at a price of $0. The stock stands almost $5.52 off versus the 52-week high of $5.683 and $0 above the 52-week low of $0.162. But in several cases high influential ownership could give a false signal to value investors, and can't be reconciled with the original intent of the strategy. The current price change puts the market capitalization at $9.12 mln. Also, the Hold rating count is 1 as of 10/19/17. During last 3 month period, -3.49% of total institutional ownership has changed in the company shares.

The company's consensus rating on Reuter's scale slipped from 2.29 to 2.22 during a month. ARGS 's 20-day moving average now sits above its 100-day moving average.

Separately, Zacks Investment Research raised shares of Argos Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, July 11th. The stock recovered 15.69% since its low point and has performed 6.54% year-to-date.

Other reports by Iphone Fresh

Discuss This Article